Revenue (Tables)

12 Months Ended

Apr. 29, 2022

Revenue from Contract with Customer [Abstract]

The table below illustrates net sales by segment and division for fiscal years 2022, 2021, and 2020:


	Net Sales by Fiscal Year
(in millions)	2022		2021		2020
Cardiac Rhythm & Heart Failure	$	5,908	$	5,584	$	5,141
Structural Heart & Aortic	3,055		2,834		2,842
Coronary & Peripheral Vascular	2,460		2,354		2,486
Cardiovascular	11,423		10,772		10,468
Surgical Innovations	6,060		5,438		5,513
Respiratory, Gastrointestinal, & Renal	3,081		3,298		2,839
Medical Surgical	9,141		8,737		8,352
Cranial & Spinal Technologies	4,456		4,288		4,082
Specialty Therapies	2,592		2,307		2,147
Neuromodulation	1,735		1,601		1,497
Neuroscience	8,784		8,195		7,725
Diabetes	2,338		2,413		2,368
Total	$	31,686	$	30,117	$	28,913

The table below includes net sales by market geography and segment for fiscal years 2022, 2021, and 2020:


	U.S.(1)						Non-U.S. Developed Markets(2)						Emerging Markets(3)
(in millions)	Fiscal Year 2022		Fiscal Year 2021		Fiscal Year 2020		Fiscal Year 2022		Fiscal Year 2021		Fiscal Year 2020		Fiscal Year 2022		Fiscal Year 2021		Fiscal Year 2020
Cardiovascular	$	5,545	$	5,248	$	5,062	$	3,866	$	3,752	$	3,519	$	2,012	$	1,773	$	1,887
Medical Surgical	3,862		3,650		3,532		3,373		3,320		3,169		1,905		1,766		1,651
Neuroscience	5,753		5,456		5,122		1,801		1,724		1,659		1,229		1,015		945
Diabetes	974		1,171		1,204		1,085		1,019		940		279		222		224
Total	$	16,135	$	15,526	$	14,919	$	10,126	$	9,815	$	9,287	$	5,426	$	4,777	$	4,707

(1)U.S. includes the United States and U.S. territories.

(2)Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries of Western Europe.

(3)Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.